

**KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH****(A unit of Kovai Medical Centre and Hospital Limited)**

Coimbatore, Tamilnadu

SERIES 5  
DEC 2019**DEPARTMENT OF PHARMACOLOGY- NEW DRUG UPDATE***Innovation drives  
progress.*

## INSIDE THIS SERIES

### **FDA - NEW DRUG APPROVALS**

1. **Methotrexate**
2. **Voxelotor**
3. **Riluzole**
4. **Cenobamate**
5. **Givosiran**
6. **Crizanlizumab-tmca**
7. **Adalimumab-afzb**
8. **Zanubrutinib**
9. **Cefiderocol**
10. **Luspatercept-aamt**
11. **Amoxicillin, Omeprazole and Rifabutin**
12. **Pegfilgrastim-bmez**

- *Novel drugs*
- *Former drugs  
with formulation  
change*

S.No	Drug Name	Mechanism of Action	Indications	Dosage Formulation	Date of FDA Approval
1.	<b>Methotrexate</b>	Folate analog metabolic inhibitor	Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriasis	Subcutaneous Injection	November 27, 2019
2.	<b>Voxelotor</b>	HbS (sickle hemoglobin) polymerization inhibitor	Sickle cell anemia	Tablet	November 25, 2019
3.	<b>Riluzole</b>	Glutamate inhibitor	Amyotrophic lateral sclerosis patients with dysphagia	Oral Film	November 22, 2019
4.	<b>Cenobamate</b>	Selective blocker of the inactivated state of voltage-gated sodium channel	Partial-onset seizures in adult patients	Tablet	November 21, 2019
5.	<b>Givosiran</b>	Aminolevulinate synthase 1-directed small interfering RNA	Acute hepatic porphyria	Injection	November 20, 2019
6.	<b>Crizanlizumab-tmca</b>	P-Selectin inhibitor	Prevention of vaso-occlusive crises in Sickle cell disease	Injection	November 15, 2019
7.	<b>Adalimumab-afzb</b> (Biosimilar)	Tumor necrosis factor blocker	Rheumatoid arthritis, Juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Crohn's disease & Ulcerative colitis, Plaque psoriasis	Injection	November 15, 2019
8.	<b>Zanubrutinib</b>	Bruton's tyrosine kinase inhibitor	Adult patients with Mantle cell lymphoma who have received at least one prior therapy	Capsule	November 14, 2019
9.	<b>Cefiderocol</b>	Siderophore cephalosporin - inhibits bacterial cell wall synthesis	Complicated urinary tract infections- in patients with limited / no alternative treatment options	Injection	November 14, 2019
10.	<b>Luspatercept-aamt</b>	First-in-class erythroid maturation agent. Recombinant fusion protein that binds several endogenous TGF- $\beta$ superfamily ligands, thereby diminishing Smad2/3 signaling	Transfusion-dependent Beta-thalassemia-associated anemia	Injection	November 8, 2019
11.	<b>Amoxicillin, Omeprazole and Rifabutin</b>	Amoxicillin inhibits cell wall biosynthesis, Omeprazole inhibits proton pump, Rifabutin inhibits DNA-dependent RNA polymerase	<i>Helicobacter pylori</i> infection	Delayed-Release Capsule	November 4, 2019
12.	<b>Pegfilgrastim-bmez</b> (Biosimilar)	PEGylated growth colony-stimulating factor	Reduce the incidence of Febrile neutropenia in patients treated with chemotherapy	Injection	November 4, 2019

**COMPILED & EDITED by**

Department of Pharmacology  
KMCHHSR, Coimbatore, 641014

Kindly Mail Your Suggestions To:

[hodpharmacology@gmail.com](mailto:hodpharmacology@gmail.com)

Access this series  
through the KMCH website

[www.kmchihsr.edu.in](http://www.kmchihsr.edu.in)